File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adaptation Of International Guidelines For Metastatic Colorectal Cancer: An Asian Consensus

TitleAdaptation Of International Guidelines For Metastatic Colorectal Cancer: An Asian Consensus
Authors
Issue Date2014
Citation
Clinical Colorectal Cancer, 2014, v. 13 n. 3, p. 145-155 How to Cite?
AbstractBackground Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). Methods A multidisciplinary expert panel, consisting of 23 participants from ten Asian and two European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Results Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional ‘real-world’ experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with capecitabine, tegafur-uracil (UFT) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild-type tumor types. For KRAS mutant tumor types, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU and oxaliplatin) is preferred for initial therapy in Asian patients. Conclusion The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus may change as more data become available.
Persistent Identifierhttp://hdl.handle.net/10722/202736

 

DC FieldValueLanguage
dc.contributor.authorCheng, ALen_US
dc.contributor.authorLi, Jen_US
dc.contributor.authorVaid, AKen_US
dc.contributor.authorMa, Ben_US
dc.contributor.authorTeh, CSen_US
dc.contributor.authorAhn, JBen_US
dc.contributor.authorBello, Men_US
dc.contributor.authorCharoentum, Cen_US
dc.contributor.authorChen, LTen_US
dc.contributor.authorde Lima Lopes Jr, Gen_US
dc.contributor.authorHo, GFen_US
dc.contributor.authorKong, HLen_US
dc.contributor.authorLam, KOen_US
dc.contributor.authorLiu, TSen_US
dc.contributor.authorPark, YSen_US
dc.contributor.authorSriuranpong, Ven_US
dc.contributor.authorSudoyo, AWen_US
dc.contributor.authorWang, JYen_US
dc.contributor.authorZhang, Jen_US
dc.contributor.authorZhang, SZen_US
dc.contributor.authorCiardiello, Fen_US
dc.contributor.authorKohne, CHen_US
dc.contributor.authorShaw, Men_US
dc.contributor.authorKim, TWen_US
dc.date.accessioned2014-09-19T09:33:31Z-
dc.date.available2014-09-19T09:33:31Z-
dc.date.issued2014-
dc.identifier.citationClinical Colorectal Cancer, 2014, v. 13 n. 3, p. 145-155en_US
dc.identifier.urihttp://hdl.handle.net/10722/202736-
dc.description.abstractBackground Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). Methods A multidisciplinary expert panel, consisting of 23 participants from ten Asian and two European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Results Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional ‘real-world’ experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with capecitabine, tegafur-uracil (UFT) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild-type tumor types. For KRAS mutant tumor types, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU and oxaliplatin) is preferred for initial therapy in Asian patients. Conclusion The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus may change as more data become available.en_US
dc.languageengen_US
dc.relation.ispartofClinical Colorectal Canceren_US
dc.titleAdaptation Of International Guidelines For Metastatic Colorectal Cancer: An Asian Consensusen_US
dc.typeArticleen_US
dc.identifier.emailLam, KO: lamkaon@hku.hken_US
dc.identifier.authorityLam, KO=rp01501en_US
dc.identifier.doi10.1016/j.clcc.2014.06.004en_US
dc.identifier.hkuros236295en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats